of TAK activity. A ROC curve was used to determine the predictive value of TC/HDL-C ratio in patients group. Results: The TG level was higher in patients with TAK than in the controls (p=0.000). The TC, LDL-C, and HDL-C levels were significantly lower in patients with TAK than in the controls (p=0.000, p=0.000, and p=0.000, respectively). The HDL-C level was significantly lower in the active TAK group than in the inactive TAK group (p=0.005). The TC/HDL-C ratio was significantly increased in patients with disease activity (p=0.001), and it exhibited a positive relationship with the high-sensitivity C-reactive protein level (r=0.234, p=0.003) and Kerr score (r=0.219, p=0.031). In addition, the TC/HDL-C ratio of 3.698 was determined as a predictive cut-off value of TAK (sensitivity 61.0%, specificity 78.6%, area under the curve=0.743) (Figure 1) .
Conclusions:
For the first time, we showed that serum levels of TC, LDL-C, and HDL-C were significantly lower in patients with TAK, and the TC/HDL-C ratio has a positive relationship with the disease activity of TAK, suggesting that the TC/HDL-C ratio may be a potential indicator for monitoring the disease activity of patients with TAK.
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